Skip to main content

Table 3 Crude and adjusted competing-risk analysis for all-cause mortality and end-stage kidney disease (ESKD) in patients with chronic kidney disease

From: Impact of lower body mass index on risk of all-cause mortality and infection-related death in Japanese chronic kidney disease patients

 

All-cause mortality

ESKD

Univariate

SHR

95% CI

P

SHR

95% CI

P

BMI group, lower

1.34

1.13

1.60

0.001

1.05

0.96

1.16

0.293

Multivariate

SHR

95% CI

P

SHR

95% CI

P

 Age group, elder

2.88

2.17

3.83

<.001

0.88

0.74

1.04

0.120

 Gender, male

1.30

0.86

1.96

0.208

1.46

1.10

1.93

0.009

 BMI group, lower

1.26

1.04

1.52

0.017

1.03

0.92

1.15

0.658

 Albumin, < 4 g/dl

1.40

0.91

2.16

0.124

2.06

1.57

2.68

<.0001

 Smoking, yes

1.87

1.14

3.08

0.014

1.40

1.00

1.94

0.047

 Diabetes, yes

1.19

0.80

1.77

0.393

1.52

1.16

2.01

0.003

 CVD history, yes

2.75

1.85

4.10

<.001

0.60

0.44

0.83

0.002

 MBP group, higher

0.81

0.66

0.98

0.030

1.16

1.03

1.31

0.013

 CKD stage, higher

1.06

0.91

1.23

0.483

6.34

5.21

7.71

<.0001

 Proteinuria, yes

1.27

0.81

2.00

0.301

2.83

1.87

4.27

<.0001

  1. Crude and adjusted competing risks for all-cause mortality and ESKD were calculated. BMI Q4 was used as reference. Bold font indicates statistical significance (P < 0.05). Covariates in multivariable-adjusted models included age, sex, serum albumin, smoking, diabetes, history of cardiovascular disease, mean blood pressure, CKD stage stratifications, and proteinuria. Abbreviations: SHR subdistribution hazard ratio, 95% CI 95% confidence interval, BMI body mass index, CVD cardiovascular disease, MBP mean blood pressure, CKD chronic kidney disease
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us